
APHIA 2026éå¬ã¬ããŒã ïœãã©ãµãŽã§ã«ãã§ç¹°ãåºããããå ç«éºäŒåŠãšç§»æ€å»çã®æåç·ïœ

5æ25æ¥ãã28æ¥ãŸã§ã®4æ¥éãæ²ŒæŽ¥åžã®ã³ã³ãã³ã·ã§ã³æœèšããã©ãµãŽã§ã«ãããäŒå Žã«ãã¢ãžã¢å€ªå¹³æŽå°åã®ç§»æ€å»çã»å ç«éºäŒåŠåéã®åœéåŠäŒãAPHIA 2026ããéå¬ãããŸãããäžçååœããç ç©¶è ãå»çåŸäºè ãæ€æ»æè¡è ãäŒæ¥é¢ä¿è ãéãŸã£ã4æ¥éãäžçã¬ãã«ã®å»çã®ãããã¯ãŒã¯ãããæ²ŒæŽ¥ã§ã®ã¥ããšç¹ããããããªç¹å¥ãª4æ¥éãšãªããŸãããä»åã¯ãã®æ§åã«ã€ããŠã¬ããŒãããŠãããŸãã
ãã©ãµãŽã§ã«ãã§éå¬ããããAPHIA2026ïŒAsia-Pacific Histocompatibility and Immunogenetics Association ConferenceïŒã
é è¡å¹¹çްèç§»æ€ããåºåœ¢èåšç§»æ€ãå ç«éºäŒåŠã现èçæ³ããã€ãªã€ã³ãã©ããã£ã¯ã¹ãªã©ãç§»æ€å»çã®ããŸããŸãªåéã®é¢ä¿è ãéçµããåœéäŒè°ã§ãã
ãšãé£ããèšèããã£ã±ãåºãŠããŠãæžããŠããç§ã®é ã®äžããããããŒã¯ããã£ã±ãæµ®ããã§ããŸãã®ã§ã
ãªãã¹ãåããããããåã¿ç ããŠæžããŠããããšæããŸãã
ãªãŒã¹ãã©ãªã¢ããã¥ãŒãžãŒã©ã³ããã¿ã€ãäžåœãã€ã³ããªã©ã¢ãžã¢å€ªå¹³æŽå°åã®ç ç©¶è
ãèšåºå»ãªã©çŽ200人ãäžå ã«äŒããä»åã®äŒè°ã
ãäœã®å
ç«ã®ããã¿ãããèåšç§»æ€ããªã©ã«ã€ããŠãææ°ã®æ
å ±ãå
±æãããŸããã

1æ¥ç®ïŒ5æ25æ¥ïŒïŒããããéå¹ïŒäžçãç¹ãç¬¬äžæ©
忥ã¯éäŒåŒã®åŸãã·ãããŒã®ããã»ãããææã®ç¹å¥è¬æŒããå§ãŸããŸããã
ããŒãã¯ã骚é«ç§»æ€ã«ããã亀差æ§èŠç¹ããã®å ¬å¹³æ§ïŒEquity with an intersectional lens in Bone Marrow TransplantationïŒã
åãããããæžããšãã¿ããªãå ¬å¹³ã«ç§»æ€ãåããããããã«ããã«ã¯ïŒããšããã話ã
ã·ãããŒã®ã»ã³ãã»ãã³ã»ã³ãã»ãã«ã¹ã»ãããã¯ãŒã¯ã®èšåºããã³æ€æ»è¡æ¶²åŠè ããããŠãã¥ãŒãµãŠã¹ãŠã§ãŒã«ãºå€§åŠã®éåžžå€ææãåããŠããããã»ãããææã
ãªãŒã¹ãã©ãªã¢ããã¥ãŒãžãŒã©ã³ããã¯ãããäººçš®ã»æ§å¥ã»ç€ŸäŒçµæžçç¶æ³ãåããããã¹ãŠã®æ£è
ããã®æ²»çæçžŸãåäžãããããã
æ°ããæè¡ãç ç©¶ææããããã驿°çãªã¢ãããŒãããååœãååãåãäœå¶ã¥ããã«ã€ããŠå¥®éããŠããŸãã
2æ¥ç®ïŒ5æ26æ¥ïŒïŒäžçã®æå 端å»çãè©°ãŸã£ãäžæ¥

2æ¥ç®ã¯ãé è¡å¹¹çްèç§»æ€ãããŒãã«ãæããå€ãŸã§äžçãããã¯ã©ã¹ã®çºè¡šãæèŠäº€æããã³ã¹ãããã§è¡ãããŸããã
ããã°ã©ã ã¯å€§ããåããŠä»¥äžã®4ã€ã®ããŒããäžå¿ã«å±éããŸããã
ååïŒéªšé«ã»é è¡å¹¹çްèç§»æ€ã®æåç·
æäžçªãããã©ãããã°ãã£ãšå®å šã«ãå ¬å¹³ã«ç§»æ€å»çãå±ããããã§ãããïŒããããããŒãšæ£è ã®ãããã³ã°ç²ŸåºŠãé«ããŠæ²»çæçžŸãã±ã¢ã®è³ªãåäžãããã«ã¯ïŒããšãã£ãè°è«ããäžçååœã®ç ç©¶çºè¡šãè¡ãããŸããã
ãæŒååŸïŒç§»æ€å»çã®ãããã³ã°ãæ¯ããæ°æè¡ã®ç޹ä»
æ€æ»ã®ã¹ããŒããæ£ç¢ºããã°ããšäžããããã®ãææ°ã®ãã¯ãããžãŒãæ©æã«é¢ããã»ãããŒãéå¬ãããŸããã
ååŸïŒãããé£ç ã«æãã现èçæ³ããšãå ç«ãã®æå 端
ããŸå€§æ³šç®ã®ãCAR-TïŒã«ãŒãã£ïŒçްèçæ³ããªã©ããããé£ç ïŒSLEãªã©ïŒã®æ°ããæ²»çæ³ã«é¢ããé©ãã®ç ç©¶ææãã·ã§ã¢ãããŸããã
倿¹ãå€ïŒæªæ¥ãæ ãè¥æã®çºè¡šïŒäº€æµäŒ
倿¹ã«ã¯åŠçãè¥æç ç©¶è ãã¡ã®åªããçºè¡šã衚地ããã»ãã·ã§ã³ããããå€ã¯ãã¯ã€ã³ïŒããŒãºããçæã«ããªã©ãã¯ã¹ããé°å²æ°ã§ãã¹ã¿ãŒçºè¡šã亀æµãæ·±ããŸããã
3æ¥ç®ïŒ5æ27æ¥ïŒïŒãåºåœ¢èåšç§»æ€ãææçãšå ç«ã®åœéå šäœäŒè°ãšäº€æµããŒãã£ãŒ

3æ¥ç®ã¯ãåºåœ¢èåšç§»æ€ïŒè èã»èèã»å¿èãªã©èåšã®ç§»æ€ïŒã«ã€ããŠã®å šäœäŒè°ãè¡ãããŸããã
äŒè°ã®å 容
è èç§»æ€ã®ææ°ç¶æ³
éHLAæäœæ€æ»ïŒç§»æ€ããèåšãäœã«æçµ¶ãããªãã調ã¹ãè¡æ¶²æ€æ»ïŒ
ABOè¡æ¶²åã®é©åæ§
ææçãšå ç«ã®é¢ä¿
ãªã©ãèåšç§»æ€ãããå®å šã«æåãããããã®å€§åãªããŒãã話ãåãããŸããã
ãã®æ¥ã¯æ¥æ¬äººã®å士ã®ç»å£ããããŸããã

åœç«åœéå»çç ç©¶æïŒNIGHMïŒã²ãã å»åŠç§åŠãããžã§ã¯ã責任è
ãåãã埳氞åå¿å士ãã
ã¹ã¿ã³ãã©ãŒãè¡æ¶²ã»ã³ã¿ãŒïŒSBCïŒã®ç ç©¶ç§åŠã»æè¡ãªãŒããŒãšããŠ12幎éå€åããŠãã倧添å·åè±å士ããããããçºè¡šãè¡ããŸããã
å€ã«ã¯äŒå Žãç§»ããŠãªããŒãµã€ãããã«ã§ã®ããŒãã£ãŒã

å€ã¯æ²ŒæŽ¥ãªããŒãµã€ãããã«ã§ãã£ããŒããŒãã£ãŒãè¡ãããåå è å士ã®äº€æµãæ·±ãŸããŸããã
ãªãŒããã³ã°ã¯ãæ¥æ¬é ã®é æšœã®èïŒé¡ïŒãæšæ§ã§å©ãå²ããé¡éãã
ïŒå²ä»¥äžã®åå è
ãå€åœäººã®ãã®æèŠªäŒã
åããŠèŠãã§ããããé¡éããã®æ§åã«åå è
ã¯è峿ޥã
ã

ããããããã»ããããã»ãããããŒãã®3åç®ã§ã¿ããªã§äžæã«æšæ§ãæ¯ãèœãšããŠèãå²ããã§ããããšã¬ã¯ãã£ãŒããŠãç¡äºã«é¡å²ããè¡ãããšãã§ããŸããã
ãå¯å¶œå€ªéŒãã«ããå倪éŒã®æŒå¥

é¡å²ãã®åŸã«ã¯å倪éŒã®æŒå¥ãã
é岡çåŸ¡æ®¿å Žåžã§ãç¥çéããè
æœèšãä¿è²åãä»è·è人çŠç¥æœèšãéå¶ããã瀟äŒçŠç¥æ³äººå¯å²³äŒããã"å©çšè
ã®å¿ã®æœ€ãã®ããã«"ãšãè·å¡ã®æ¹ãã¡ã倪éŒãå§ããå€ªéŒæŒå¥è
éå£ãçµæããããšãããå¯å¶œå€ªéŒãã
1977幎ã«çµæããããå¯å¶œå€ªéŒãã¯ãæœèšãå©çšãã幌å
ãã幎å¯ããéããè
ã«å€ªéŒãæããã»ããåœå
ã»æµ·å€ã§ã®æŒå¥æŽ»åãè¡ã£ãŠããŸãã

倪éŒã®æŒå¥ãå§ãŸããšãããŒãã£ãŒã«åå ãã人ã»ãšãã©ãã¹ããã§æŒå¥ãæ®åœ±ããŠã楜ãããã«çãäžãã£ãŠããã®ãå°è±¡çã§ããã
æçµæ¥ïŒ5æ28æ¥ïŒïŒãã€ãªã€ã³ãã©ããã£ã¯ã¹ïŒçç©æ å ±ç§åŠïŒã§æªæ¥ã®å»çãèãã
æçµæ¥ã®ããŒãã¯ãçŸä»£ã®å»çãã²ãã ç ç©¶ã«æ¬ ãããªããã€ãªã€ã³ãã©ããã£ã¯ã¹ïŒçç©æ
å ±ç§åŠïŒã§ããã
倧éã®ããŒã¿ãã³ã³ãã¥ãŒã¿ãŒã§åæããããAIãæŽ»çšãããããæå
ç«¯ã®æè¡ã«ã€ããŠãå
å®ããã»ãã·ã§ã³ãè¡ãããŸããã

倧添å·åè±å士ã®è¬æŒ
æ¥æ¬äººç ç©¶è ã®å€§æ·»å·åè±å士ã¯ãHLAè¡æž åãã«ã€ããŠçºè¡šããŸããã
HLAãšã¯ïŒ
ãHLAïŒããçœè¡çæåïŒHuman Leukocyte AntigenïŒãšã¯ã
èµ€è¡çãé€ãã»ãŒãã¹ãŠã®çްèãäœæ¶²ã«ååšããã¿ã³ãã¯è³ªã§ãããã°ã现èã®è¡æ¶²åãã®ãããªãã®ã ããã§ãã
å ç«ã·ã¹ãã ããèªåã®çްèããšãå€ããäŸµå ¥ãããŠã€ã«ã¹ãªã©ã®æµããæ£ããèŠåããããã®ã»ã³ãµãŒïŒéµãšéµç©Žã®é¢ä¿ïŒãšããŠåããŠããã®ã ããããã®ãããèåšç§»æ€ã骚é«ç§»æ€ãè¡ãéã«ããããŒãšã¬ã·ããšã³ãã®çžæ§ïŒé©åæ§ïŒãå·Šå³ããæ¥µããŠéèŠãªèŠçŽ ãšãªããŸãã
ã现èã®ã¢ã€ãã³ãã£ãã£ïŒèº«åèšŒææžïŒããšããããæåãªãã§ããã
HLAãšããäœã®ç®å°ã«ã€ããŠãã³ã³ãã¥ãŒã¿ãŒã䜿ã£ãææ°ã®åææ¹æ³ãããã£ãšããããã®äººãå©ããããæªæ¥ã®æ²»çã«ã€ããŠãªã©ã®è©±ãåºãŸããã
äŒæ¥ããŒã¹ãå å®

äŒè°å®€ã®é£ãã«ã¯ããPOSTER & SPONSOR Exhibition ROOMãäŒæ¥ããŒã¹ãèšããããŸããã
ãã€ãããæ¥ãDKMSã®ã¹ã¿ããã®æ¹ã«ãæ¥æ¬ã®å°è±¡ããèãããŠã¿ãŸããã
ãæ¥æ¬ã蚪ããã®ã¯ãåããŠããšãŠãè¯ãã£ããããããªãã®ãæ©èœããŠããŠãé£ã¹ç©ãããããã人ãåªãããç®±æ ¹ã®ç¥ç€Ÿã蚪ããŠãããæ»åšã䌞ã°ããŠãåºå³¶ãå
µåº«ã倧éªã京éœãå¥è¯ãå·¡ãäºå®ããšãæ¥æ¬ãæºå«ããäºå®ãšã®ããšã
ã話ãèãããŠããã ããŠãããããæ°æã¡ã«ãªããŸããã

ãDKMSãã¯ããã€ãã«æ¬éšã眮ãäžçæå€§çŽã®éªšé«ãããŒç»é²æ©é¢ã
äžçäžã§1,250äžäººä»¥äžã®ãããŒãç»é²ããŠããŠããããŸã§ã«125,000人以äžã®æ£è
ã«é è¡å¹¹çްèã®ç§»æ€ãæäŸããŠããŸãã
ãããã£ãäžççãªåãçµã¿ã«ãã£ãŠãåœã®ã€ãªãããå°ããã€åºãããç§ãã¡ã倧åãªèª°ãã®åœã仿¥ãæ¯ããããŠãããã§ããã
äžäººã®åæããé ãé¢ãã誰ãã®æªæ¥ãç
§ããã
ãããªåžæãæããç¬éã§ãã
çµç¹å§å¡é·ã€ã³ã¿ãã¥ãŒ

çµç¹å§å¡é· Dianne De Santis å
çãããã³ã¡ã³ããããã ããŸããïŒ
Q1ïŒä»åã®åŠäŒã沌接ã§éå¬ããããšæ±ºããçç±ã¯ïŒ
ãåœéHLAã¯ãŒã¯ã·ã§ããã®éå¬å°ã§ãã£ãããšãæ±äº¬å°çåŸã®æµ·å€åå è
ã«ãšã£ãŠã¢ã¯ã»ã¹ããããã£ãããšãå¯å£«å±±ã«è¿ãæ¯ãã®ããããªæ¯è²ã楜ãããããšããããŠãã©ãµãŽã§ã«ããé§
ãããã«ãããè¿ãèšåãå
å®ããŠããããšãããæ²ŒæŽ¥ãéžã³ãŸããã
Q2ïŒAPHIA2026ã®ææã«ã€ããŠãç¹ã«éèŠã ãšæããç¹ã¯ïŒ
ã驿°çãªãµã€ãšã³ã¹ãšèšåºé¢ã®é²å±ããããŠåå¥åå»çãæšé²ããå ŽãšãªããŸãããã¢ãžã¢å€ªå¹³æŽå°åã®ç§åŠè
ã»èšåºå»ã»äŒæ¥ã®ååãä¿é²ã§ããããšããããŠæ¬¡äžä»£ã®è¥æç ç©¶è
ãã¡ãèªèº«ã®ç ç©¶ãçºè¡šãããããã¯ãŒã¯ãç¯ããèªç¥ãåŸãèå°ãæäŸã§ããããšã倧ããªææã ãšæããŠããŸãã
Q3ïŒãã©ãµãŽã§ã«ãã®äŒå Žã®å°è±¡ãæ¥æ¬ã®å°è±¡ãæããŠãã ããã
ããã©ãµãŽã§ã«ãã¯ãè¬å ã»å±ç€ºã¹ããŒã¹ã»åç§äŒçšã®éšå±ãæã£ãçæ³çãªäŒå Žã§ãããJR沌接é§
ããåŸæ©åã§ãå®¿æ³æœèšã«ãè¿ããæµ·å€ããã®åå è
ã«ãšã£ãŠã®ã¢ã¯ã»ã¹ãè¯å¥œã§ãããæããéæŸæã®ããé°å²æ°ã§ãäŒè°ã«ãµããããçŽ æŽãããå Žæã§ããã

ããŸããäºåå±ã®çããŸã«ã¯å¿ã®ããã£ãçŽ æŽããããã¹ãã¿ãªãã£ã§éå¶ã®çްéšãŸã§äžå¯§ã«ã察å¿ããã ããçµç¹å§å¡ã»åå è
ã»ã¹ãã³ãµãŒã®å
šå¡ã«ãšã£ãŠãã¹ã ãŒãºã§æž©ããäŒè°äœéšãå®çŸããŠãã ãããŸããã
ãæ¥æ¬ã¯æ¬åœã«çŽ æŽãããã£ãã§ãã人ã
ã¯æž©ãã芪åã§ãæ¬æãšè±ããªæåã«æºã¡ãçŸããåœã§ããã
APHIA 2026 éäŒ

2026幎5æ25æ¥ãã28æ¥ãŸã§ããã©ã¶ãŽã§ã«ãã§éå¬ããã ãAPHIA2026ãã¯ç¡äºã«éäŒããŸããã
4æ¥éã«ããããäžçäžããéãŸã£ãç ç©¶è
ãå»åž«ãã¡ãææ°ã®ç¥èŠãå
±æããæŽ»çºãªè°è«ãå±éããå®ãå€ãäŒè°ãšãªããŸããã
ç¹ã«æ¥æ¬äººç ç©¶è
ã®çºè¡šããé¡å²ãã»å倪éŒãšãã£ãæ¥æ¬æåãéãã亀æµã®å Žããåå è
å士ã®çè§£ãæ·±ããè¯ãæ©äŒãšãªã£ãããšãšæããŸãã
ç§»æ€å»çã®æåç·ã«æºããå€ãã®å°éå®¶ãäžå ã«äŒããã倿§æ§ãå ¬å¹³æ§ããããŠé©æ°æ§ããšããããŒãã®ããšã§æèŠã亀ãããããšã§ãä»åŸã®èšåºãç ç©¶ã®çºå±ã«å€§ããªåºæ¿ãäžããæ©äŒããããæ²ŒæŽ¥ããçãŸããŸããã
ç§èªèº«ããç§»æ€å»çã®æå 端ãšåœéçãªç ç©¶è ã®ç±æãéè¿ã§æããããšãã§ãããšãŠãå€ãã®åºæ¿ãšåŠã³ãåŸãããšãã§ããŸããã

ã©ã€ã¿ãŒïŒå®®å·çç±çŸïŒæ²ŒæŽ¥çµæžæ°èïŒ